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Acellular vaccines against Bordetella pertussis were 
introduced in Australia in 1997. By 2000, these vaccines 
had replaced whole-cell vaccines. During 2008–2012, a 
large outbreak of pertussis occurred. During this period, 
30% (96/320) of B. pertussis isolates did not express the 
vaccine antigen pertactin (Prn). Multiple mechanisms of Prn 
inactivation were documented, including IS481 and IS1002 
disruptions, a variation within a homopolymeric tract, and 
deletion of the prn gene. The mechanism of lack of expres-
sion of Prn in 16 (17%) isolates could not be determined 
at the sequence level. These findings suggest that B. per-
tussis not expressing Prn arose independently multiple 
times since 2008, rather than by expansion of a single Prn- 
negative clone. All but 1 isolate had ptxA1, prn2, and ptxP3, 
the alleles representative of currently circulating strains in 
Australia. This pattern is consistent with continuing evolution 
of B. pertussis in response to vaccine selection pressure.
Bordetella pertussis is the gram-negative coccobacil-lus that causes the respiratory disease pertussis, also 
known as whooping cough. The incidence of pertussis 
infection and related deaths decreased dramatically after 
implementation of immunization with a whole-cell vaccine 
(WCV) during the 1950s. Because of side effects of WCV, 
such as high rates of fever and local reactions, and vari-
able efficacy of WCVs, a less reactogenic acellular vaccine 
(ACV) was developed in the 1980s. ACVs have now re-
placed WCVs in many industrialized countries for primary 
and booster vaccinations against pertussis.
Although ACV formulations differ in the number of 
component pertussis antigens, the vaccine used in Austra-
lia contains pertussis toxin (Ptx), pertactin (Prn), and fila-
mentous hemagglutinin (Fha). A 5-component (Ptx, Prn, 
Fha, fimbrial antigen [Fim] 2, and Fim3) ACV is used for 
short periods in some regions (1). ACVs were introduced 
for the fourth and fifth doses in most states in Australia 
during 1997 and for all doses during 1999 (Figure 1). South 
Australia introduced ACVs for all doses in 1997. The cur-
rent vaccination schedule for pertussis comprise 3 primary 
doses of ACV at 2, 4, and 6 months of age, and a booster 
vaccination at 4 years of age. A booster vaccination with 
ACV at 18 months of age, which was introduced in 1985, 
was removed from the National Immunization Program in 
Australia in 2003, and an adult-formulated ACV was intro-
duced for children at 12–17 years of age in school-based 
programs in 2004 (2,3).
Since 1991, data on reported pertussis cases show 
that outbreaks occurred in Australia in 1996–1997, 2001, 
and 2004, and a series of outbreaks occurred in different 
regions starting in 2008 (Figure 1) (2,3). Multiple factors 
probably contributed to the resurgence of pertussis in high-
income countries that had long-standing pertussis immuni-
zation programs. These factors include waning immunity 
(exacerbated by the change from WCVs to ACVs and, in 
Australia, cessation of the booster vaccination at 18 months 
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of age) and increased use of more sensitive diagnostic tests, 
such PCR (4).
An additional possible contributing factor is evolution 
of B. pertussis through vaccine-driven adaptation (5). The 
most prominent recent changes in circulating B. pertussis 
strains are polymorphisms within genes encoding 2 of the 
3 main virulence factors (Ptx and Prn) contained in the vac-
cine. Variations have also been reported in ptxP, the pro-
moter of the ptx operon (6). In Australia, we have shown by 
single nucleotide polymorphism (SNP) typing that among 
B. pertussis isolates, ptxP3–containing strains predominate 
(7), and these strains belong to SNP cluster I (8,9).
Surveillance of recent B. pertussis isolates in several 
countries has identified prn deletions and gene disruptions, 
which lead to lack of expression of mature Prn (10–13). 
This protein is a 69-kDa adhesin that aids B. pertussis at-
tachment to epithelial cells and is one of the most polymor-
phic virulence genes within B. pertussis (it has 13 docu-
mented alleles) (5). SNPs and differences in the number of 
amino acid (GGFGP and PQP) repeats contribute to varia-
tion within the prn gene; variations are usually limited to 2 
regions known as region 1 and region 2.
In this study, we identified B. pertussis isolates that do 
not express Prn (Prn negative) from a set of isolates collect-
ed in Australia during 1997–2012. We also characterized 
the causes of their lack of expression and evaluated trends 
in the proportion of Prn-negative isolates over this period.
Methods
Bacterial Strains and Growth
A total of 453 B. pertussis isolates were available for 
this study; 133 isolates collected during 1997–2008 and 
194 collected during 2008–2010 have been described (9). 
A total of 126 additional isolates collected from Westmead 
Hospital (Sydney, New South Wales, Australia) and Prin-
cess Margaret Hospital for Children (Perth, Western Aus-
tralia, Australia) during 2011–2012 were also included this 
study. Although specific clinical information about the 
source of isolates was not available, isolates were obtained 
from patients who lived in large urban areas and who had 
PCR-confirmed pertussis infections. The number of avail-
able isolates in 2011–2012 was relatively small because 
several participating laboratories discontinued pertussis 
culture in favor of only direct PCR testing.
All B. pertussis isolates were grown on Bordet Gengou 
agar (Becton Dickinson, Sparks, MD, USA) supplemented 
with 10% defibrinated horse blood (Oxoid, Basingstoke, 
UK) at 37°C for 3–5 days before subculture and incubation 
at 37°C for 24 h. All cultures were examined for hemolytic 
activity indicating expression of the virulent (Bvg+) phase 
before being collected and resuspended in saline to an opti-
cal density at 650 nm = 1 for Western immunoblotting.
Western Immunoblotting
The Ptx, Prn, and Fha proteins were detected by West-
ern immunoblotting as described (10,11,14). Bacterial 
suspensions were mixed with Laemmli buffer containing 
5% β-mercaptoethanol and boiled for 5 min. Proteins sepa-
rated by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis were transferred to a polyvinylidene difluoride 
membrane at 100 V for 1 hr. Membranes were blocked 
with 5% (wt/vol) skim milk powder in wash buffer for 1 hr 
and incubated overnight with mouse polyclonal antibod-
ies against Ptx, Fha, and Prn diluted 1:1,000 with Tris-
buffered saline (TBS) containing 1% Tween 20. After 3 
washes with TBS containing 1% Tween 20, membranes 
were incubated for 1 h with sheep antimouse monoclonal 
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Figure 1. Pertussis cases/100,000 
population in Australia, 2008–2012, 
since mandatory reporting was 
instituted in 1991 and changes to 
pertussis vaccination schedule, 
including introduction of whole-cell 
vaccine (WCV) booster vaccinations 
for 4–5-year-old children in 1994–
1995 and introduction of acellular 
vaccine (ACV) booster vaccinations 
in 1997. By 1999–2000, ACVs were 
used for all pertussis vaccinations. 
In 2003, the booster vaccinations 
for children 18 months of age 
was removed and replaced with a 
booster vaccination for children 15–
17 years of age (3). 
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antibodies in TBS plus 5% skim milk and 0.1% Tween 
20. Antigen–antibody complexes were visualized by che-
miluminescence on a LAS3000 imager (Fujifilm, Tokyo, 
Japan). The minimum detectable amount with this method 
was 1 ng of specific protein.
Genotyping and prn Gene Sequencing
Isolates were genotyped for fim3, prn, and ptxP al-
leles as described (7–9). Isolates that had not already been 
typed were characterized by SNP cluster and SNP pro-
file as described by Octavia et al. (8), multilocus variable 
number tandem repeat analysis (MLVA) as described by 
Kurniawan et al. (1) typing of prn, fim3, and ptxP alleles 
(6,15). Relationships among SNP profiles and clusters 
were defined by Octavia et al. (8) and are shown in on-
line Technical Appendix Figure 1 (wwwnc.cdc.gov/EID/
article/20/4/13-1478-Techapp1.pdf).
For isolates that did not express Prn, overlapping 
primers reported by Fry et al. (16) were used to amplify 
a predicted 2,869-bp region that included the signal pep-
tide region and the prn gene. The prn promoter region was 
also sequenced to detect any changes. Each PCR mixture 
contained ≈30 ng DNA, 10 mmol/L Tris-HCl (pH 8.3), 50 
mmol/L KCl, 2.5 mmol/L MgCl2, 100 µmol/L of each de-
oxynucleotide, 10 pmol/L of each primer, 2.5 units of Taq 
polymerase, and milliQ water (Millipore, Billerica, MA, 
USA). Products were then sequenced on an Automated 
DNA Sequence Analyzer ABI3730 (Applied Biosystems, 
Foster City, CA, USA) to determine the complete prn 
gene, which included region 1 and region 2. All sequences 
were aligned against prn gene sequences identified by 
Mooi et al. (17). 
Results
Identification and Distribution of B. pertussis  
Not Expressing Prn
The 320 B. pertussis isolates obtained during 2008–
2012 were from 5 states in Australia: New South Wales 
(116 isolates), Queensland (37), South Australia (47), 
Victoria (30), and Western Australia (90). All 96 (30) 
isolates identified by Western immunoblot as not express-
ing Prn were obtained after 2008. Examples of Western 
immunoblots are shown in online Technical Appendix 
Figure 2. The other 133 isolates obtained before 2008 ex-
pressed Prn and were from SNP clusters I and II or were 
unclustered. The distribution of Prn-negative isolates in 
individual states is shown in the Table. Only isolates from 
Western Australia and New South Wales were available 
for all years during 2008–2012; no isolates were avail-
able from South Australia or Victoria during 2011–2012 
or from Queensland during 2008–2009 and 2012. All iso-
lates expressed Ptx and Fha.
The Prn-negative strains were first identified in isolates 
collected in 2008, when they made up 5% (2/39) of the iso-
lates. By 2012, the proportion of Prn-negative isolates had 
increased to 78% (28/36) (Figure 2). In Western Australia 
and New South Wales, where isolates were available for all 
years, there was a progressive increase from 3% in 2009 to 
78% in 2012 (online Technical Appendix Figure 3). Lack 
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Figure 2. Number and percentage 
of pertactin (Prn)–negative 
Bordetella pertussis isolates in 
Australia, 2008–2012. During this 
period, 320 B. pertussis isolates 
obtained in New South Wales, 
Queensland, South Australia, 
Victoria, and Western Australia 
were identified as expressing 
Prn or not expressing Prn by 
using Western immunoblotting. 
The increasing percentage of 
Prn-negative isolates each year 
during 2008–2012 was 5%, 12%, 
23%, 53%, and 78% respectively. 
Data for individual states and 
years can be found in the Table. 
Gray bars indicate number of 
isolates expressing Prn, and 
white bars indicate number of 
isolates not expressing Prn. 
Rapid Increase in Pertactin-deficient B. pertussis
of isolates from Queensland, Victoria, and South Australia 
in various years was related to changes in laboratory prac-
tice (cultures no longer obtained) or decreased numbers in 
a post-epidemic period, rather than any systematic differ-
ences in collection. It is unlikely that different patterns of 
circulating B. pertussis differed in these regions.
The increase in Prn-negative isolates during 2011–
2012, in comparison with 2008, was significant (p<0.05, 
by Fisher exact test with multiple test correction). All but 
1 Prn-negative isolate had the ptxA1, prn2, and ptxP3 al-
leles and belonged to SNP cluster I; the exception, L1378, 
had ptxA1 and prn1 but not ptxP3, and was not assigned to 
any SNP cluster. In addition, the Prn-negative isolates had 
new MLVA types that were closely related to MT27 and 
MT114, both of which are currently circulating in Australia 
(9), although MT27 still predominates.
Sequence Analysis of prn Gene of  
Prn-deficient Isolates
Mechanisms of disruption, identified by sequencing 
the prn region, including the signal peptide, of 80/96 Prn-
negative isolates, are shown in Figure 3. Seventy-seven 
(82%) isolates had IS elements located between region 1 
and region 2; in prn, a 1049-bp IS481 was inserted in the 
forward direction in 13 isolates and in the reverse direction 
in 58 isolates. A 1,037-bp IS1002 was inserted in the for-
ward direction in 6 isolates, which has not been described 
in the prn region. All IS element disruptions were at posi-
tion 1613 and were flanked by a 6-bp repeat (ACTAGG) at 
the 5′ end and AGGCAG at the 3′ end (Figure 3).
One isolate had no IS within prn but had an additional 
guanine residue at position 1185 between region 1 and re-
gion 2, which resulted in a stop codon at amino acid posi-
tion 749. Two isolates from South Australia that had SNP 
profile SP13 were nontypeable. For prn, multiple pairs of 
PCR primers specific for the prn gene (15–19) failed to 
amplify a product, which indicated deletion of the entire 
gene. IS disruptions, deletions, or other variations were 
not detected in prn or the prn promoter region of 16 Prn-
negative isolates. Details of the 96 Prn-negative isolates, 
including individual prn, fim, and ptxP alleles, SP, MLVA 
type, and mechanism of prn disruption, are shown in the 
online Technical Appendix Table.
Discussion
In the 2 regions of Australia where isolates were avail-
able for all years during 2008–2012, Prn-negative B. per-
tussis isolates increased from >10% to ≈80% of B. pertus-
sis isolates over this period. Prn-negative strains have been 
isolated in several countries that have high coverage for 
vaccination but have not been shown to constitute such a 
high proportion of circulating B. pertussis (12,13,20,21). 
Japan was the first country to implement ACVs against per-
tussis in 1981, and the proportion of Prn-negative isolates 
reported from countrywide surveillance during 2005–2009 
was 32% (18/57). In France, where ACVs have been used 
since 1998, originally as booster vaccinations, and then for 
all doses since 2002 (11), Ptx-negative and Fha-negative 
isolates were first obtained in 2003, although only Prn- 
negative isolates have increased and were reported to make 
up 13.3% of 120 isolates analyzed in 2011 (10).
The Prn-negative B. pertussis isolates have also been 
identified in Finland and the United States (13,21,22). The 
United States introduced ACVs as booster vaccinations in 
1991, but not until 1997 were all 5 primary doses replaced 
with ACVs (23). Although Finland replaced WCVs with 
ACVs at a later time (booster vaccinations in 2003 and pri-
mary vaccinations in 2005), both countries detected Prn-
negative isolates during 2011–2012. Long-term temporal 
analysis has not been performed to determine whether such 
isolates are increasing over time.
In comparison, until 2001 and 2009, respectively, Rus-
sia (24) and Senegal (25), which currently use only WCVs, 
have not reported Prn-negative isolates. However, it is dif-
ficult to draw a definitive conclusion on the correlation of 
timing of emergence of Prn-negative strains with timing of 
introduction of ACVs. Extensive analysis of isolates from 
earlier years from different countries would be required.
Multiple mechanisms of lack of expression of Prn 
have been reported (11,12). Insertion of IS481 into the 
prn gene in either the forward or reverse direction was 
still the main mechanism of disruption (73.9%). This dis-
ruption occurred at the same conserved site identified in 3 
isolates from the United States (nt position 1613) (21) and 
9 isolates from Japan (nt position 1598) (12). The 15-bp 
difference in position is caused by an additional GGFGP 
repeat in prn2 in the isolates in our study and those from 
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Table. Distribution of pertactin-positive and protactin-negative Bordetella pertussis isolates in 5 states, Australia, 2008–2012* 
Year 
State 































2008 18 0 0  – – –  13 2 13  1 0 0  5 0 0 
2009 52 0 0  – – –  17 9 35  10 1 9  18 2 10 
2010 8 6 43  3 6 67  5 1 17  17 1 6  14 1 7 
2011 6 17 74  21 7 25  – – –  – – –  8 15 65 
2012 2 7 78  – – –  – – –  – – –  6 21 78 
*Pos, positive; Neg, negative; –, no isolates were obtained. 
 
RESEARCH
the United States, compared with those from Japan, which 
have prn1.
Six isolates in our study had an additional IS1002 
disruption at nucleotide position 1613 (Figure 2), which 
confirmed that the 6-bp repeat site flanking IS elements is 
conserved (26). The lower number of isolates with IS1002 
disruptions could be caused by fewer copies of IS1002 
than IS481 in the genome (6 for IS1002 in Tohama I com-
pared with 238 for IS481). Disruption of virulence genes 
by IS1002 has been reported; unlike B. parapertussis and 
B. bronchiseptica, B. pertussis does not express O antigen 
because of an IS1002-mediated deletion of the O-antigen 
locus (27). All isolates in this study that had the IS1002 
disruption were collected in 1 state in Australia (New South 
Wales) and might have arisen from a single outbreak. More 
isolates are needed to determine whether this finding is in-
dicative of an expanding clone.
Another mechanism of disruption is an 84-bp deletion 
of the signal peptide (nucleotide position 26). This deletion 
was observed in 24 isolates from Japan (12) and 2 isolates 
from Finland (13) but was not observed in any of  the iso-
lates in our study. However, 2 of the isolates apparently had 
the entire prn gene deleted.
In 1 isolate (L1502), an additional G residue in a homo-
polymeric tract of G residues resulted in a downstream stop 
codon. Truncations caused by stop codons in the prn gene 
were reported in 7 isolates from the United States (21), but 
they were at nucleotide position 1273 and the actual base 
change was not specified. Phase variation has been associat-
ed with variation in other B. pertussis genes, including fim2, 
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Figure 3. Variations in pertactin (prn) gene of Prn-negative Bordetella pertussis isolates, Australia, 2008–2012, Ninety-six B. pertussis 
isolates were identified as Prn negative. Eighty of these isolates had 1 of 4 mechanisms of prn disruption: IS481 (in forward and reverse 
directions) and IS1002, which were inserted at the ACTAGG motif within prn, or an extended homopolymeric tract of G residues (n = 
1). Lower case letters indicate residues that are conserved in all IS disruptions, and red letters indicate differences in IS disruptions. 
Positions of nucleotides have been numbered relative to the first start codon of sequence AJ011092 (17). The prn gene of 2 isolates was 
not amplified by PCR with a combination of primers from published studies (15–19), which indicated a deletion of the entire gene. Sixteen 
isolates that had no gene disruptions were also observed. 
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fim3, fimX, and bapC (28), and is a common mechanism of 
phase variation in other pathogenic microorganisms (29,30).
A large proportion (17%, 16/96) of Prn-negative iso-
lates had no sequence change detected in the prn gene or its 
promoter upstream, which indicated that other mechanisms 
must have been responsible for inactivating Prn expres-
sion. These 16 isolates belong to 3 SNP profiles; 8, 7, and 
1 isolates belonging to SP13, SP14, and SP18, respectively, 
which suggests 3 independent inactivating events. Inactiva-
tion of expression could have occurred at the transcriptional 
or translational level. Our preliminary investigations showed 
that 3 of these Prn-negative isolates produced prn gene tran-
scripts. A consequence of Prn inactivation without sequence 
variation of the prn gene is that it can be detected only at the 
protein level. Until mechanisms are identified, culturing of 
isolates will still be needed to monitor B. pertussis.
The increase in isolates that do not express a specific 
antigen has been documented only recently in Australia and 
other countries that use ACVs. The predominant isolates 
we identified are from SP13, SP14, or SP16, and all but 1 
had the ptxA1, prn2, ptxP3 genotype. We have also shown 
that isolates with different SNP profiles can be affected by 
the same IS disruptions, and conversely, different IS dis-
ruptions can affect isolates with the same SNP profiles.
Most of the recently isolated Prn-negative strains from 
the United States have the prn2 allele, which has been the 
predominant type since the 1990s (21,22). However, mu-
tations causing inactivation of expression of the prn gene 
differ from those reported in this study and elsewhere. Prn-
negative isolates characterized by Otsuka et al.  (12) had 
the prn1, ptxA2, ptxP1 genotype and were from MT186 or 
related MT194 or MT226. Our previous analysis showed 
that MT186 belongs to SNP cluster V; this type is unrelated 
to isolates examined in the current study, which belong to 
SNP cluster I (online Technical Appendix Figure 1), but 
was affected by the same IS disruption mechanisms. Two 
isolates from Finland that had prn1 were also reported to 
be Prn negative because of deletions, although prn2 is the 
current predominant allele (13). Thus, the combination of 
SNP typing, antigen gene typing, and prn gene disruption 
mechanisms clearly demonstrates that isolates that do not 
express the prn gene from Australia and other countries 
do not belong to the same clone and that the recent almost 
simultaneous appearance and expansion of Prn-negative 
isolates in several countries were independent events rather 
than global spread of a single clone.
The multiple origins of Prn-negative isolates also point 
strongly to selective pressure on the bacterium. Therefore, 
it is conceivable that these Prn-negative isolates are more 
likely to evade a vaccine-induced immune response. How-
ever, the relative contribution of Prn to pertussis disease has 
not been clearly established. Various studies using prn mu-
tants have shown that mutants that do not express Prn do not 
colonize mouse lungs as well as isolates that express Prn (31) 
but were more invasive in epithelial cells and persist for a 
longer period (32). The Prn-negative strains have a greater 
growth advantage in vitro than their Prn-positive counter-
parts (12). This growth advantage can be beneficial in main-
taining a high level of transmissibility between hosts, which 
is consistent with increasing numbers of infections with Prn-
negative isolates identified in Australia and elsewhere.
Whether these isolates have greater or lesser virulence 
than Prn-positive strains is unclear. In contrast to lack of pro-
duction of Ptx, loss of Prn does not seem to affect B. pertus-
sis lethality in mice, possibly because of the range of auto-
transporters within B. pertussis that can compensate for the 
role of Prn (10). In a retrospective study, no differences were 
found in severity of symptoms or duration of hospitalization 
between infants infected with Prn-positive and Prn-negative 
strains in France (20); the only major difference observed 
was the longer period from onset of pertussis symptoms to 
time of hospitalization among infants whose B. pertussis 
isolate was Prn negative. Regardless of Prn expression, vac-
cination reduced the severity of disease and the likelihood of 
being admitted to intensive care, which suggests that even 
an incomplete course of primary vaccination provides some 
protection against severe pertussis (20).
The results in this study highlight the emerging trend of 
Prn-deficient B. pertussis isolates circulating in Australia. 
In addition to changes observed in prn, ptxA, ptxP, and fim 
genes of currently circulating strains, this study and other 
studies have reported the increasing prevalence of isolates 
not expressing Prn in many countries that have a high up-
take of ACV. The overall effect of lack of expression of an 
antigen on herd immunity is unknown. Emergence of Prn-
negative isolates is a relatively recent phenomenon that has 
affected currently circulating B. pertussis isolates. Wheth-
er strains not expressing Prn continue to increase locally 
or globally and affect vaccine effectiveness and bacterial 
pathogenicity is unknown. Continued monitoring of geno-
typic and phenotypic properties of B. pertussis is required 
to better understand the effects of vaccination on the evolu-
tion of the organism.
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